We provide five in vitro-produced monoclonal antibodies that are specific to human Lp-PLA2. They can be used for the development of quantitative immunoassays which enable the detection of Lp-PLA2 from plasma samples. In addition, we provide recombinant human Lp-PLA2.
The newly FDA-approved heart failure drug (Entresto®) has caused significant excitement as the clinical studies have shown considerably better therapy outcomes for patients suffering from heart failure.
HyTest was able to continue its strong growth during the first half of 2015. Consolidated revenue grew to 9.2 million euros, which represented an increase of 18% compared to the first half of the previous year.
We are delighted to announce the news that HyTest has been granted a patent in the United States for SES-BNP technology and IGFBP-4 fragments in Finland, France, Germany, Sweden and the United Kingdom.